Experimental and Clinical Pharmacology
New drugs: transparency
- Aust Prescr 2009;32:26-7
- 1 June 2009
- DOI: 10.18773/austprescr.2009.040
ISSUE 3 JUNE
Access to information about drugs is essential for the quality use of medicines. Since 2003 Australian Prescriber has therefore recorded details about the willingness of pharmaceutical companies to disclose the information that supported the Australian approval of their new products.1 These details are published as the T(ransparency)-score at the end of each new drug comment in Australian Prescriber.
Table 1 shows the responses to requests for evaluation data between January 2007 and January 2009. The Editorial Executive Committee of Australian Prescriber is pleased to report that there has been an improvement since the previous reports were published.1,2 Most manufacturers now provide some information to assist in the preparation of the new drug comments. The Editorial Executive Committee hopes this trend to increased transparency continues.
Table 1 Pharmaceutical company responses to requests for clinical evaluation data 2007–2009
| Company | Drug | |
 manufacturer provided clinical evaluation
|
||
| Amgen | romiplostim | |
| Baxter Healthcare | factor VIII inhibitor bypassing fraction | |
| Bristol-Myers Squibb | abatacept, dasatinib, perflutren | |
| Ferring | carbetocin | |
| Genzyme | anti-thymocyte globulin | |
| Hospira | ibandronic acid | |
| Pfizer | maraviroc, varenicline, ziprasidone | |
| Wyeth | temsirolimus | |
| manufacturer provided additional useful information
|
||
| Boehringer Ingelheim | pramipexole | |
| Janssen-Cilag | paliperidone | |
| Merck Sharp & Dohme | fosaprepitant | |
| Servier | ivabradine | |
| manufacturer provided only the product information
|
||
| Abbott | paricalcitol | |
| Amgen | panitumumab | |
| Baxter Healthcare | human protein C | |
| Biogen Idec | natalizumab | |
| Boehringer Ingelheim | tipranavir | |
| Cedarglen Investments | galsulfase | |
| CSL | sitaxentan | |
| Delpharm | nitric oxide | |
| Eli Lilly | duloxetine | |
| Genzyme | idursulfase, laronidase | |
| GlaxoSmithKline | human papillomavirus vaccine, lapatinib | |
| Merck Sharp & Dohme | zoster virus vaccine | |
| Novartis | nilotinib, ranibizumab, telbivudine | |
| Pharmatel Fresenius Kabi | pentastarch | |
| Sanofi-Aventis | insulin glulisine | |
| Schering-Plough | olmesartan | |
| UCB Pharma | rotigotine | |
 manufacturer declined to supply data
|
||
| AstraZeneca | fulvestrant | |
| Celgene | lenalidomide | |
| Eli Lilly | exenatide | |
| Janssen-Cilag | darunavir | |
 manufacturer did not respond to request for data
|
||
| Genzyme | alglucosidase | |
| Merck Sharp & Dohme | raltegravir, sitagliptin |
|
